Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Xenon Pharmaceuticals (NASDAQ:XENE) but lowers the price target from $62 to $60.
August 12, 2024 | 9:41 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Xenon Pharmaceuticals but lowers the price target from $62 to $60.
The Buy rating suggests continued confidence in the stock, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100